90 related articles for article (PubMed ID: 15271314)
1. Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome.
Jennens RR; Rosenthal MA; Lindeman GJ; Michael M
Urol Oncol; 2004; 22(3):193-6. PubMed ID: 15271314
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Kuenen BC; Tabernero J; Baselga J; Cavalli F; Pfanner E; Conte PF; Seeber S; Madhusudan S; Deplanque G; Huisman H; Scigalla P; Hoekman K; Harris AL
Clin Cancer Res; 2003 May; 9(5):1648-55. PubMed ID: 12738717
[TBL] [Abstract][Full Text] [Related]
3. Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.
Rini BI; Jaeger E; Weinberg V; Sein N; Chew K; Fong K; Simko J; Small EJ; Waldman FM
BJU Int; 2006 Oct; 98(4):756-62. PubMed ID: 16827904
[TBL] [Abstract][Full Text] [Related]
4. Understanding the importance of smart drugs in renal cell carcinoma.
Patard JJ; Rioux-Leclercq N; Fergelot P
Eur Urol; 2006 Apr; 49(4):633-43. PubMed ID: 16481093
[TBL] [Abstract][Full Text] [Related]
5. [A case of renal cell carcinoma associated with von Hippel-Lindau disease and the necessity for family genetic diagnosis].
Nanri M; Uda M; Iguchi Y; Gouya N; Toma H; Kihara T
Hinyokika Kiyo; 1999 Nov; 45(11):755-8. PubMed ID: 10637737
[TBL] [Abstract][Full Text] [Related]
6. First-Line sunitinib in patients with renal cell carcinoma (RCC) in von Hippel-Lindau (VHL) disease: clinical outcome and patterns of radiological response.
Roma A; Maruzzo M; Basso U; Brunello A; Zamarchi R; Bezzon E; Pomerri F; Zovato S; Opocher G; Zagonel V
Fam Cancer; 2015 Jun; 14(2):309-16. PubMed ID: 25391617
[TBL] [Abstract][Full Text] [Related]
7. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Lara PN; Quinn DI; Margolin K; Meyers FJ; Longmate J; Frankel P; Mack PC; Turrell C; Valk P; Rao J; Buckley P; Wun T; Gosselin R; Galvin I; Gumerlock PH; Lenz HJ; Doroshow JH; Gandara DR;
Clin Cancer Res; 2003 Oct; 9(13):4772-81. PubMed ID: 14581348
[TBL] [Abstract][Full Text] [Related]
8. Single case of renal cell carcinoma and endocrine pancreatic head cancer occurring with von Hippel-Lindau disease.
Osawa A; Sumiyama Y; Watanabe M; Tanaka H; Asai K; Enomoto T; Matsukiyo H; Kanai R; Takeuchi Y; Oharazeki T
J Hepatobiliary Pancreat Surg; 2006; 13(2):174-80. PubMed ID: 16547682
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
Heymach JV; Desai J; Manola J; Davis DW; McConkey DJ; Harmon D; Ryan DP; Goss G; Quigley T; Van den Abbeele AD; Silverman SG; Connors S; Folkman J; Fletcher CD; Demetri GD
Clin Cancer Res; 2004 Sep; 10(17):5732-40. PubMed ID: 15355900
[TBL] [Abstract][Full Text] [Related]
10. The current role of angiogenesis inhibitors in the treatment of renal cell carcinoma.
Choueiri TK; Bukowski RM; Rini BI
Semin Oncol; 2006 Oct; 33(5):596-606. PubMed ID: 17045089
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of F-18 FDG-PET in a long-term hemodialysis patient with renal cell carcinoma and pheochromocytoma.
Ozawa N; Okamura T; Koyama K; Hamazawa Y; Senzaki H; Tanabe S; Ikemoto S; Inoue Y
Ann Nucl Med; 2007 Jun; 21(4):239-43. PubMed ID: 17581724
[TBL] [Abstract][Full Text] [Related]
12. A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Mita MM; Rowinsky EK; Forero L; Eckhart SG; Izbicka E; Weiss GR; Beeram M; Mita AC; de Bono JS; Tolcher AW; Hammond LA; Simmons P; Berg K; Takimoto C; Patnaik A
Cancer Chemother Pharmacol; 2007 Feb; 59(2):165-74. PubMed ID: 16736151
[TBL] [Abstract][Full Text] [Related]
13. Sunitinib treatment of metastatic renal cell carcinoma in von Hippel-Lindau disease.
Tsimafeyeu I
J Cancer Res Ther; 2015; 11(4):920-2. PubMed ID: 26881543
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of bortezomib for patients with advanced renal cell carcinoma.
Kondagunta GV; Drucker B; Schwartz L; Bacik J; Marion S; Russo P; Mazumdar M; Motzer RJ
J Clin Oncol; 2004 Sep; 22(18):3720-5. PubMed ID: 15365068
[TBL] [Abstract][Full Text] [Related]
15. [Second-line thalidomide/IL-2 therapy in metastatic kidney cancer--results of a pilot study].
Schrader AJ; Heidenreich A; Hegele A; Olbert P; Varga Z; Hofmann R
Aktuelle Urol; 2006 Nov; 37(6):429-35; quiz 423-4. PubMed ID: 17099831
[TBL] [Abstract][Full Text] [Related]
16. Novel antiangiogenic therapies for renal cell cancer.
Gordon MS
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6377S-81S. PubMed ID: 15448034
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib for the treatment of benign and malignant neoplasms from von Hippel-Lindau disease: A single-arm, prospective phase II clinical study from the PREDIR group.
Oudard S; Elaidi R; Brizard M; Le Rest C; Caillet V; Deveaux S; Benoit G; Corréas JM; Benoudiba F; David P; Gaudric A; Hammel P; Joly D; Timsit MO; Méjean A; Richard S
Oncotarget; 2016 Dec; 7(51):85306-85317. PubMed ID: 27852035
[TBL] [Abstract][Full Text] [Related]
18. Combination targeted therapy in advanced renal cell carcinoma.
Sosman J; Puzanov I
Cancer; 2009 May; 115(10 Suppl):2368-75. PubMed ID: 19402058
[TBL] [Abstract][Full Text] [Related]
19. [Testicular metastasis and local recurrence of renal cell carcinoma after nephron-sparing surgery in von Hippel-Lindau disease].
Nemoto K; Shimizu H; Kimura G
Hinyokika Kiyo; 2007 Mar; 53(3):163-5. PubMed ID: 17447484
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapy of renal cell cancer.
Wysocki PJ; Zolnierek J; Szczylik C; Mackiewicz A
Curr Opin Investig Drugs; 2008 Jun; 9(6):570-5. PubMed ID: 18516756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
